William Blair upgraded 10x Genomics (TXG) to Outperform from Market Perform. The firm is positive on the company’s role in enabling the high-resolution biological insights needed to build decision-enabling models and considers that execution and profitability have improved, the analyst tells investors in a research note. William Blair adds that on AI, 10x is well positioned to capitalize on the growing demand for large-scale biological data sets to train AI models.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- Is Cathie Wood Turning Bearish on Bullish (BLSH) Stock?
- FIG, CRCL, BLSH: Why Cathie Wood Just Bet $8M on Figma Despite Google’s (GOOGL) New Threat, Sells Crypto Stocks
- Cathie Wood’s ARK Investment buys 92K shares of 10x Genomics today
- 10x Genomics falls -13.8%
- Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS